Compass Pathways rises as it launches US training grants for psilocybin care

COMPASS Pathways

14/04/2026 11:35

** Shares of biotech firm Compass Pathways CMPS.O rise 2.6% to $5.92 premarket

** Co says it launched a U.S. grant program to help train healthcare providers to deliver its experimental psilocybin treatment for hard‑to‑treat depression

** Says it will fund up to three U.S. organizations to develop training materials, including modules specific to its COMP360 drug, ahead of any potential launch

** Says the program aims to prepare doctors and clinics to provide consistent care if the therapy is approved

** COMP360, a synthetic form of psilocybin, has U.S. FDA breakthrough status and is under review for patients with treatment‑resistant depression - CMPS

** As of last close, stock down ~16% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))